|

Five Telling Takeways from Benzinga Psychedelics Capital Conference

BySarah Abelsohn



Five Telling Takeways from Benzinga Psychedelics Capital Conference

Join our Newsletter (scroll to the bottom of the page and sign up):

Psychedelic Spotlight

Follow us on Twitter:
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@psycspotlight

The first ever Benzinga Psychedelics Capital Conference was held on April 19 at the Fontainbleau Hotel in Miami Beach. It preceded the 14th iteration of the Cannabis Capital Conference and represented a return to form for Benzinga after years lost to pandemic pandemonium.

The conference brought together leaders of the biggest publicly traded psychedelics companies with investors from across North America. It was a day full of unique networking opportunities, insight on opportunities in this burgeoning space, and a chance to be in the room with the leaders who are endeavoring to take the psychedelics industry to the next level.

Psychedelic Spotlight had the opportunity to attend, so I wanted to share five telling takeaways from the Benzinga Psychedelics Capital Conference scene.

1. Expect Another Benzinga Psychedelics Capital Conference in 2023

2. Irwin Naturals Affirms Its ‘First Mover Advantage’

3. Innovators From Other Sectors Seek Psychedelic Synergy

4. Women Have an Advocate in Felicity Pharma CEO Olivia Mannix

5. Super Mario Was Way Ahead of His Time

#psychedelics #benzinga #psychedelicstocks

source

Similar Posts

  • MindMed Expands MICRODOSING trials (BIG MMED/MMEDF stock UPDATE)

    Listen, Videos

    In today’s episode “MindMed Expands Microdosing Trials”, we’ll discuss a Big MindMed Stock Update.

    On January 12th, MindMed ticker symbol (NEO: MMED ) and (OTC:MMEDF) put out a Press Release entitled MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers. In other words, MindMed is expanding its LSD microdosing studies from just looking at how they can help those with adult ADHD, to how they could affect a more general population. This is BIG news the MindMed team and us shareholders.

    As I mentioned in one of our previous episodes : “Why I’m More Excited About MindMed’s 18-MC than its LSD treatments”, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. And If these trials come back successful, it’ll be the beginning of more LSD microdosing studies for MindMed.

    In this episode, we will do three things:
    1:We’ll read the Press Release and discuss what it means, in layman’s terms
    2: We’ll enter the Speculation Zone to discuss the potential effects of this move
    3: We’ll discuss how this expansion affects MindMed stock as an investment

    So, what does this all mean for investors?
    Can we assume that MindMed’s LSD microdosing to treat ADHD trial is going well? This, even without the new trials, would be very good news for us long term investors. Moreover, this new study shows that MindMed is continuing to expand their potential product pipeline which will also look great for the MMED/ MMEDF Stock.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF